AB1236 OSTEOPOROSIS AND FRACTURES IN PATIENTS UNDERGOING CHRONIC CORTICOSTEROID THERAPY

Background Glucocorticoids are widely used for the treatment of various rheumatic diseases and one major risk factors bone fragility associated fractures. However, beyond randomized clinical trials, there is little evidence in actual practice. Objectives Our aim to evaluate appearance osteoporosis fractures patients undergoing corticosteroid therapy. Methods We performed an observational retrospective descriptive study with Vasculitis (several subtypes) or Polymyalgia Rheumatica (PMR) diagnosed, who had received regimens doses at least 5 mg/day prednisone (or equivalent) a period not less than 3 months, which was monitored next 2 years. Results included 234 (62.4% females) mean age onset corticosteroids 75.8 years duration 58 months. The most represented disease PMR, 183 (78.2%), followed by Large Vessel (12.4%), ANCA positive Small (4.3%), negative (3.4%), lower proportion Medium vasculitis other such as Relapsing Polychondritis. Furthermore, 29 (12.39%) previous fractures, while 32 (13.68%) suffered more after start therapy, being hip its frequent location (4.7%), vertebrae (3.8%). Likewise, until new 4.5 Even without reaching statistical significance, we observed greater (80.5 years), higher presence female gender (81.25%) fracture (18.75%) In addition, 32.91% densitometric beginning Table 1. Comparison between different therapeutic options Treatment Patients n (%) New Fractures Fracture-free time: average Alendronate 31 (13.25) (16.13) 5.39 Ibandronate 6 (2.57) (50) 6.51 Risedronate 54 (23.07) (11.11) Zoledronate 8 (3.42) (62.5) 5.03 Bazedoxifene 1 (0.43) 0 (0) 1.19 Denosumab 38 (16.24) (15.79) 4.41 Teriparatide 10 (4.27) 4 (40) 5.2 No 86 (36.75) (3.49) 3.88 association zoledronate (P=0.012), tendency ibandronate (P=0.07). discreet entity these differences could be explained effect produced small number taking into account, moreover, fact that our Rheumatology Department systematically carry out assessment decide whether when treatment, also prescribing powerful fracture. Finally, did observe significant fracture-free time among options. Conclusion have frequency older gender. Less quantitative prevention ibandronate, no clear time. REFERENCES: NIL. Acknowledgements: Disclosure Interests None Declared.